Bosutinib

Bosutinib Basic information

Product Name:

Synonyms:

3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-Methoxyphenyl)aMino]-6-Methoxy-7-[3-(4-Methyl-1-piperazinyl)propoxy]-;Bosutinib(TINIBS );4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile Bosutinib (SKI-606);WAY-173606;Bosulif(bosutinib);SKI-606;SKI 606 - Bosutinib;4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile

CAS:

MF:

C26H29Cl2N5O3

MW:

530.45

EINECS:

700-455-1

Product Categories:

Intermediates & Fine Chemicals;Pfizer compounds;-;Aromatics Compounds;Pharmaceuticals;API;Aromatics;Heterocycles;Inhibitors;Bosutinib ada@tuskwei.com whatsapp;8618031153937

Mol File:

 

Bosutinib Chemical Properties

Melting point 

116-120 ºC

density 

1.36

storage temp. 

room temp

solubility 

DMSO: ≥15mg/mL

form 

powder

color 

off-white to light brown

CAS DataBase Reference

 

Safety Information

Hazard Codes 

Risk Statements 

Safety Statements 

WGK Germany 

3

HS Code 

29335990

MSDS Information

 

Bosutinib Usage And Synthesis

Description

In September 2012, the US FDA approved bosutinib (also referred to as SKI-607) for the treatment of relapsed or refractory chronicmyeloid leukemia (CML) for patients with resistance or intolerance to prior therapy. The National Cancer Institute estimates that in 2012, 5430 men and women were diagnosed with CML and 610 died of CML. First and second-line therapies for the treatment of CML include imatinib, dasatinib, and nilotinib. Bosutinib, which was initially identified as a Src inhibitor, was later found to be a dual inhibitor of Bcr–Abl (IC₅₀=1.4 nM) and Src family kinases (IC₅₀=3.5 nM). Bosutinib inhibits 16 of 18 imatinib-resistant forms of Bcr–Abl expressed in murine myeloid cell lines. In preclinical in vivo studies, bosutinib at 15 mg/kg administered orally for 5 days caused regression of K562 CML tumors in nude mice and in BaF₃ tumors expressing wild type or different imatinib-resistant Bcr–Abl mutants at varying doses. A manufacturing process for the synthesis of bosutinib monohydrate has been reported that employs a key three-component cyclization reaction involving an aniline, a cyanoacetamide intermediate, and triethyl orthoformate followed by cyclization using phosphorous oxytrichloride and an optimized hydration procedure.

Chemical Properties

Pale Yellow Solid

Originator

Wyeth (United States)

Uses

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively.

Uses

A novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.

Uses

peripheral vasolidator increases cerebral blood flow, potential therapeutic for Altzheimer’s disease, cognitive impairment and dementia

Definition

ChEBI: An aminoquinoline that is 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline bearing additional cyano and methoxy substituents at positions 3 and 6 respectively.

Brand name

Bosulif